Evidence map›Paper›PMID 28074068›Full record

ArticleLeukemia2017

A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome.

A D Kelly, H Kroeger, J Yamazaki, R Taby, F Neumann, S Yu, J T Lee, B Patel, Y Li, R He and 10 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Biodistribution, Tumor Detection, and Radiation Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. CpG Island Methylator Phenotype-A Hope for the Future or a Road to Nowhere?International journal of molecular sciences · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

A D KellyFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
H KroegerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J YamazakiFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
R TabyDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
F NeumannDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S YuFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
J T LeeFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
B PatelFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Y LiGenomics Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.
R HeDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S LiangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Y LuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M CesaroniFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
S A PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
S M KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C E Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
F RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H M KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J JelinekFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
J-Pj IssaFels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
The University of Texas MD Anderson Cancer Center · USTemple University · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7M
Regulators of Cancer-Specific DNA Hypermethylation.R01CA158112 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI ISSA, JEAN-PIERRE J. · 2012 to 2016
$1.6M
Randomized study of combined epigenetic therapyR01CA121104 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ISSA, JEAN-PIERRE J. · 2007 to 2011
$1.5M
NCI NIH HHS P30 CA006927NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA121104NCI NIH HHS R01 CA158112
6 · The paper itself

Abstract

Genetic changes are infrequent in acute myeloid leukemia (AML) compared with other malignancies and often involve epigenetic regulators, suggesting that an altered epigenome may underlie AML biology and outcomes. In 96 AML cases including 65 pilot samples selected for cured/not-cured, we found higher CpG island (CGI) promoter methylation in cured patients. Expanded genome-wide digital restriction enzyme analysis of methylation data revealed a CGI methylator phenotype independent of IDH1/2 mutations we term AML-CGI methylator phenotype (CIMP) (A-CIMP

Indexed as

CpG IslandsDNA MethylationAdolescentAdultAgedDatasets as TopicDNA, NeoplasmFemaleHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteMaleMiddle AgedMutationPhenotypePilot ProjectsDNA, NeoplasmIDH1 protein, humanIDH2 protein, humanIsocitrate Dehydrogenase

Identifiers

PMID28074068
PMCPMC5537054
OpenAlexW2577128554

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.